Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

The federal agency’s new alert is about counterfeit drugs claiming to have semaglutide — the key ingredient in weight loss ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...